For the first time, there is an FDA-approved drug made specifically for primary membranous nephropathy, an autoimmune kidney disease and one of the most common causes of nephrotic syndrome in adults. In mid-November 2026, the FDA approved obinutuzumab (Gazyva, Genentech/Roche) for adults with primary membranous nephropathy who are at risk of disease progression, to induce remission of proteinuria, the leak of protein into the urine.
For patients, the most practical part of this story is that membranous nephropathy is tracked almost entirely through lab tests: urine protein, blood albumin, kidney function, and a disease-specific antibody called anti-PLA2R. If you need the basics first, read our guide to protein in urine: causes, symptoms and risks.
What the FDA approved, and why it matters
Until now, doctors treated membranous nephropathy with drugs borrowed from other conditions, such as rituximab, calcineurin inhibitors like tacrolimus, or cyclophosphamide with steroids, all used off-label. The approval is based on the phase 3 MAJESTY trial, published in the New England Journal of Medicine. It enrolled 142 adults with primary membranous nephropathy, who received either intravenous obinutuzumab or oral tacrolimus.
- Complete remission at two years (urine protein-to-creatinine ratio of 0.3 g/g or lower with stable kidney function): about 37% with obinutuzumab versus 6% with tacrolimus.
- Complete or partial remission at two years: 50% versus about 13%, according to Roche.
- No significant difference in sustained loss of kidney function, an outcome that needs longer follow-up.
- Most common side effects: infusion reactions and upper respiratory infections; the investigators reported no new safety signals.
Obinutuzumab is a monoclonal antibody that depletes B cells, the immune cells that produce the autoantibodies driving the disease. It was already approved for certain blood cancers, lupus nephritis, and childhood idiopathic nephrotic syndrome. One caveat noted by nephrologists: MAJESTY compared it with tacrolimus, not with rituximab, so we do not yet know whether it beats the drug most kidney specialists use first.
Membranous nephropathy in brief
In membranous nephropathy, the immune system makes antibodies against a protein on podocytes, the cells that keep protein from passing from the blood into the urine. Antibody deposits damage this filter. Protein spills into the urine, blood albumin drops, and swelling (edema) develops, often in the ankles, legs, or around the eyes. Roche cites an incidence of about 1.2 new cases per 100,000 people per year in the US.
The course varies widely. Roughly a third of patients go into remission on their own, a third keep some degree of proteinuria, and a third progress toward severe kidney failure. Blood clots and infections are the main short-term complications. The disease can also be secondary to another condition, such as lupus, hepatitis B, certain medications, or cancer, so doctors always look for a cause.
Which tests can monitor or screen for this?
The first clue is often a urine dipstick positive for protein or persistently foamy urine (see foamy urine explained). These are the key tests:
| Test | What it measures | Why it matters |
|---|---|---|
| Urine protein-to-creatinine ratio (UPCR) | How much protein you lose in urine | Above about 3 g/g suggests nephrotic-range proteinuria; 0.3 g/g or lower defined complete remission in MAJESTY |
| Serum albumin | The main blood protein, which falls when protein leaks out | Below 3.0 g/dL with heavy proteinuria defines nephrotic syndrome; very low levels raise clot risk |
| Anti-PLA2R antibody (blood) | The autoantibody found in about 70% to 80% of primary cases | A positive result can support the diagnosis without a biopsy in some patients; falling levels signal response |
| Creatinine and eGFR | How well the kidneys filter | A rapid decline is a red flag that changes treatment |
| Lipid panel and electrolytes | Effects of nephrotic syndrome on the body | Cholesterol often rises sharply and is checked at follow-up visits |
The anti-PLA2R test has transformed care. Antibody levels usually fall weeks to months before urine protein does, so they give an earlier read on whether a treatment is working. For more on kidney markers, see our guides to the albumin-to-creatinine ratio, low albumin, and the kidney function panel.
What this means for you
Not everyone with membranous nephropathy needs immunosuppressive treatment. People at low risk may first receive supportive care, such as blood pressure drugs that lower proteinuria and a low-salt diet, because spontaneous remission is common. The new approval matters most for people at higher risk of progression. It may also give doctors a labeled option for patients who do not respond to rituximab, which a 2026 meta-analysis puts at 35% to 45% of patients.
An FDA label can also make insurance coverage easier, a point raised by nephrologists interviewed after the decision. Your nephrologist will weigh your urine protein, albumin, kidney function, and antibody level before choosing a therapy.
Recent scientific advances
Several 2026 studies add context to MAJESTY. A meta-analysis pooling smaller studies found remissions with obinutuzumab in patients who had never been treated, in those previously treated, and even in people whose disease resisted rituximab, with albumin rising and proteinuria falling over time. Those groups cannot be compared head to head, though.
A November 2026 expert review suggests the best candidates are people with high anti-PLA2R levels, high-risk disease, or rituximab failure or intolerance. A retrospective study found that the anti-PLA2R level measured at six months predicted remission better than proteinuria alone. In plain terms, a blood test is becoming a steering wheel for treatment decisions, not just a diagnostic tool.
When to see a doctor
- If a urine test shows protein, or your urine stays foamy day after day.
- If your ankles, legs, or eyelids swell, or you gain weight quickly without explanation.
- If you have membranous nephropathy and your albumin drops, your creatinine rises, or your anti-PLA2R level climbs again.
- Call 911 for sudden shortness of breath, chest pain, or a painful, swollen calf, which can signal a blood clot.
Glossary
- Membranous nephropathy: an autoimmune disease in which antibodies deposit on the kidney filter; "primary" means no other cause is found.
- Nephrotic syndrome: heavy protein loss in urine with low blood albumin, often with swelling and high cholesterol.
- Anti-PLA2R: an autoantibody against the phospholipase A2 receptor on podocytes, found in most primary cases.
- Podocyte: a kidney cell that keeps protein out of the urine.
- B cell: a white blood cell that produces antibodies.
- Complete remission: urine protein back to a near-normal level with stable kidney function.
FAQ
Is Gazyva the first treatment for membranous nephropathy?
It is the first drug FDA-approved specifically for adults with primary membranous nephropathy. Other medicines, such as rituximab, have been used off-label for years and remain standard options.
Can a blood test diagnose membranous nephropathy?
In someone with nephrotic syndrome and normal kidney function, a positive anti-PLA2R test can strongly support the diagnosis, and some patients can avoid a kidney biopsy. A negative test does not rule the disease out, and a biopsy is then usually needed.
What does a high anti-PLA2R level mean?
Higher levels are linked to more active disease and a higher risk of progression. A falling level during treatment is a good sign and usually comes before urine protein improves.
Can membranous nephropathy go away on its own?
Yes. Roughly a third of people with primary membranous nephropathy go into spontaneous remission, which is why doctors assess risk before starting immune-suppressing drugs.
Which tests are repeated during follow-up?
Typically urine protein-to-creatinine ratio, serum albumin, creatinine and eGFR, electrolytes, lipids, and anti-PLA2R level when the antibody was positive at diagnosis.
Sources
- Fervenza FC et al. Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy (MAJESTY trial). New England Journal of Medicine, 2026. DOI: 10.1056/NEJMoa2602678
- A Step Forward - Obinutuzumab for Membranous Nephropathy. New England Journal of Medicine, 2026. DOI: 10.1056/NEJMe2609719
- Elettreby AM et al. Treatment-Line-Specific Outcomes of Obinutuzumab in Membranous Nephropathy: A Systematic Review and Meta-Analysis. International Journal of Nephrology, 2026. DOI: 10.1155/ijne/6372570
- Juanet C et al. Could obinutuzumab be the new therapy for adults with primary membranous nephropathy? Expert Review of Clinical Pharmacology, 2026. DOI: 10.1080/17512433.2026.2761222
- Bashir K et al. Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy. Jornal Brasileiro de Nefrologia, 2026. DOI: 10.1590/2175-8239-jbn-2025-0228en
- Roche. Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy, November 16, 2026
- Healio. FDA approves Gazyva for proteinuria remission in primary membranous nephropathy, November 17, 2026
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Nephrotic syndrome in adults
- ClinicalTrials.gov. MAJESTY: obinutuzumab versus tacrolimus in primary membranous nephropathy (NCT04629248)
Other articles
- Protein in urine: causes, symptoms and risks
- Foamy urine explained: causes and risks
- Creatinine: the blood marker of kidney function
- Urinalysis results: interpretation guide
- Kidney function tests and heart disease
Understand your own blood test results with AI DiagMe
Urine protein, albumin, creatinine, eGFR: if you have a kidney panel in hand, AI DiagMe explains each value in plain language, compares it with reference ranges, and helps you prepare the right questions for your nephrologist.



